Chronic liver diseases and diabetes

Chronic liver diseases and diabetes

The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revue médicale suisse 2014-06, Vol.10 (433), p.1254, 1256-1254
Hauptverfasser: Jaafar, Jaafar, de Kalbermatten, Bénédicte, Philippe, Jacques, Scheen, André, Jornayvaz, François R
Format: Artikel
Sprache:fre
Schlagworte:
Blood Glucose - metabolism
Chronic Disease
Contraindications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - etiology
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Liver Diseases - complications
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1254
container_issue 433
container_start_page 1254, 1256
container_title Revue médicale suisse
container_volume 10
creator Jaafar, Jaafar
de Kalbermatten, Bénédicte
Philippe, Jacques
Scheen, André
Jornayvaz, François R
description The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However, diabetes, notably when associated with obesity and dyslipidemia, participates in the development of nonalcoholic fatty liver disease and to steato-hepatitis that may progress to cirrhosis and hepatocellular carcinoma. Other relations between diabetes and chronic liver disease will be discussed in this article. Finally, the indications and limits of each anti-diabetic therapy group will be discussed according to the degree of liver damage.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1544322337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1544322337</sourcerecordid><originalsourceid>FETCH-LOGICAL-p562-93170bbf8edf8ef8b89976a742d5a07bbd72cb8262314863088d0c7082b53bc73</originalsourceid><addsrcrecordid>eNo1T8tqwzAQ1KGlCWl-oRh66cUgrZ4-FtMXBHrJ3WilNVXxq1Zc6N_XoenAsAwMMztXbCuM4WUlbbVh-5w_-QojJIC8YRvQnCtrYcvu6495HFIouvRNcxFTJp8pF36Iq_BIJ8q37Lr1Xab95e7Y8fnpWL-Wh_eXt_rxUE7awFolLEdsHcWVrUNXVdZ4qyBqzy1itBDQgQEplDOSOxd5sNwBaonByh17-Iud5vFroXxq-pQDdZ0faFxyI7RS5__l2Xp3sS7YU2ymOfV-_mn-d8lftpNGuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544322337</pqid></control><display><type>article</type><title>Chronic liver diseases and diabetes</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Jaafar, Jaafar ; de Kalbermatten, Bénédicte ; Philippe, Jacques ; Scheen, André ; Jornayvaz, François R</creator><creatorcontrib>Jaafar, Jaafar ; de Kalbermatten, Bénédicte ; Philippe, Jacques ; Scheen, André ; Jornayvaz, François R</creatorcontrib><description>The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However, diabetes, notably when associated with obesity and dyslipidemia, participates in the development of nonalcoholic fatty liver disease and to steato-hepatitis that may progress to cirrhosis and hepatocellular carcinoma. Other relations between diabetes and chronic liver disease will be discussed in this article. Finally, the indications and limits of each anti-diabetic therapy group will be discussed according to the degree of liver damage.</description><identifier>ISSN: 1660-9379</identifier><identifier>PMID: 25004772</identifier><language>fre</language><publisher>Switzerland</publisher><subject>Blood Glucose - metabolism ; Chronic Disease ; Contraindications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - etiology ; Humans ; Hypoglycemic Agents - administration &amp; dosage ; Hypoglycemic Agents - therapeutic use ; Liver Diseases - complications</subject><ispartof>Revue médicale suisse, 2014-06, Vol.10 (433), p.1254, 1256-1254</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25004772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaafar, Jaafar</creatorcontrib><creatorcontrib>de Kalbermatten, Bénédicte</creatorcontrib><creatorcontrib>Philippe, Jacques</creatorcontrib><creatorcontrib>Scheen, André</creatorcontrib><creatorcontrib>Jornayvaz, François R</creatorcontrib><title>Chronic liver diseases and diabetes</title><title>Revue médicale suisse</title><addtitle>Rev Med Suisse</addtitle><description>The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However, diabetes, notably when associated with obesity and dyslipidemia, participates in the development of nonalcoholic fatty liver disease and to steato-hepatitis that may progress to cirrhosis and hepatocellular carcinoma. Other relations between diabetes and chronic liver disease will be discussed in this article. Finally, the indications and limits of each anti-diabetic therapy group will be discussed according to the degree of liver damage.</description><subject>Blood Glucose - metabolism</subject><subject>Chronic Disease</subject><subject>Contraindications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration &amp; dosage</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Liver Diseases - complications</subject><issn>1660-9379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1T8tqwzAQ1KGlCWl-oRh66cUgrZ4-FtMXBHrJ3WilNVXxq1Zc6N_XoenAsAwMMztXbCuM4WUlbbVh-5w_-QojJIC8YRvQnCtrYcvu6495HFIouvRNcxFTJp8pF36Iq_BIJ8q37Lr1Xab95e7Y8fnpWL-Wh_eXt_rxUE7awFolLEdsHcWVrUNXVdZ4qyBqzy1itBDQgQEplDOSOxd5sNwBaonByh17-Iud5vFroXxq-pQDdZ0faFxyI7RS5__l2Xp3sS7YU2ymOfV-_mn-d8lftpNGuQ</recordid><startdate>20140604</startdate><enddate>20140604</enddate><creator>Jaafar, Jaafar</creator><creator>de Kalbermatten, Bénédicte</creator><creator>Philippe, Jacques</creator><creator>Scheen, André</creator><creator>Jornayvaz, François R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20140604</creationdate><title>Chronic liver diseases and diabetes</title><author>Jaafar, Jaafar ; de Kalbermatten, Bénédicte ; Philippe, Jacques ; Scheen, André ; Jornayvaz, François R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p562-93170bbf8edf8ef8b89976a742d5a07bbd72cb8262314863088d0c7082b53bc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2014</creationdate><topic>Blood Glucose - metabolism</topic><topic>Chronic Disease</topic><topic>Contraindications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration &amp; dosage</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Liver Diseases - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaafar, Jaafar</creatorcontrib><creatorcontrib>de Kalbermatten, Bénédicte</creatorcontrib><creatorcontrib>Philippe, Jacques</creatorcontrib><creatorcontrib>Scheen, André</creatorcontrib><creatorcontrib>Jornayvaz, François R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revue médicale suisse</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaafar, Jaafar</au><au>de Kalbermatten, Bénédicte</au><au>Philippe, Jacques</au><au>Scheen, André</au><au>Jornayvaz, François R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic liver diseases and diabetes</atitle><jtitle>Revue médicale suisse</jtitle><addtitle>Rev Med Suisse</addtitle><date>2014-06-04</date><risdate>2014</risdate><volume>10</volume><issue>433</issue><spage>1254, 1256</spage><epage>1254</epage><pages>1254, 1256-1254</pages><issn>1660-9379</issn><abstract>The presence of chronic liver diseases may drastically limit the use of anti-diabetic drugs. Chronic liver diseases increase insulin resistance, and in some risk groups promote the development of diabetes. Therefore, antidiabetic treatment should be adapted to the severity of liver disease. However, diabetes, notably when associated with obesity and dyslipidemia, participates in the development of nonalcoholic fatty liver disease and to steato-hepatitis that may progress to cirrhosis and hepatocellular carcinoma. Other relations between diabetes and chronic liver disease will be discussed in this article. Finally, the indications and limits of each anti-diabetic therapy group will be discussed according to the degree of liver damage.</abstract><cop>Switzerland</cop><pmid>25004772</pmid><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1660-9379
ispartof Revue médicale suisse, 2014-06, Vol.10 (433), p.1254, 1256-1254
issn 1660-9379
language fre
recordid cdi_proquest_miscellaneous_1544322337
source MEDLINE; Alma/SFX Local Collection
subjects Blood Glucose - metabolism
Chronic Disease
Contraindications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - etiology
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - therapeutic use
Liver Diseases - complications
title Chronic liver diseases and diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20liver%20diseases%20and%20diabetes&rft.jtitle=Revue%20m%C3%A9dicale%20suisse&rft.au=Jaafar,%20Jaafar&rft.date=2014-06-04&rft.volume=10&rft.issue=433&rft.spage=1254,%201256&rft.epage=1254&rft.pages=1254,%201256-1254&rft.issn=1660-9379&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1544322337%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544322337&rft_id=info:pmid/25004772&rfr_iscdi=true